Table 2

Classification of treatment outcome


Treatment group
Treatment outcome
CQ
AQ
SP
AQ+SP
AQ+AS
14-day follow-up
ETF (%)
4/39 (10.3)
0/38 (0)
0/38 (0)
0/81 (0)*
0/80 (0)*
LCF (%)
 OTF (%)
 7/39 (17.9)
 14/39 (35.9)
 0/38 (0)*
 0/38 (0)
 0/38 (0)*
 1/38 (2.6)
 0/81 (0)*
 1/81 (1.2)
 0/80 (0)*
 0/80 (0)
LPF (%)
3/39 (7.7)
0/38 (0)
1/38 (2.6)
1/81 (1.2)
0/80 (0)
ACPR (%)
25/39 (64.1)
38/38 (100)*
37/38 (97.4)*
80/81 (98.8)*
80/80 (100)*
28-day follow-up non adjusted (PCR-uncorrected)
ETF (%)
4/36 (11.1)
0/36 (0)
0/38 (0)
0/79 (0)*
0/76 (0)*
LCF (%)
 OTF (%)
 9/36 (25.0)
 20/36 (55.5)
 3/36 (8.3)
 5/36 (13.9)
 0/38 (0)*
 2/38 (5.2)
 2/79 (2.5)*
 4/79 (5.0)
 3/76 (3.9)*
 12/76 (15.7)
LPF (%)
7/36 (19.4)
2/36 (5.6)
2/38 (5.2)
2/79 (2.5)*
9/76 (11.8)
ACPR (%)
16/36 (44.5)
31/36 (86.1)*
36/38 (94.8)*
75/79 (95.0)*
64/76 (84.3)*
28-day follow-up adjusted (PCR-corrected)
New infections (%)
4/36 (11.1)
4/36 (11.1)
1/38 (2.6)
1/79 (1.2)**
6/76 (7.9)
ETF (%)
4/36 (11.1)
0/36 (0)
0/38 (0)
0/79 (0)*
0/76 (0)*
LCF (%)
 OTF (%)
 7/36 (19.4)
 13/36 (44.4)
 1/36 (2.8)
 1/36 (2.8)
 0/38 (0)
 1/38 (2.6)
 1/79 (1.3)*
 3/78 (3.8)
 1/76 (1.3)*
 6/76 (7.9)
LPF (%)
5/36 (13.9)
0/36 (0)*
1/38 (2.6)
2/79 (2.5)*
5/76 (6.6)
ACPR (%)
20/36 (55.6)
35/36 (97.2)*
37/38 (97.4)*
76/79 (96.2)*
70/76 (92.1)*

Data presented are cumulative, failures up to day 14 of follow-up are also considered in the calculation of day 28 failure rates.

Percentages are rounded to achieve totals of 100%.

CQ, Chloroquine; AQ, amodiaquine; SP, Sulphadoxine-pyrimethamine; AS, artesunate ETF, early treatment failure; LCF, late clinical failure; LPF, late parasitological failure; ACPR, adequate clinical and parasitological response.

* Significant difference to CQ group (P < 0.05); ** Significant difference to CQ and AQ groups (P < 0.05).

Ménard et al. Malaria Journal 2007 6:65   doi:10.1186/1475-2875-6-65

Open Data